Collectively, these cellular experiments supported the inhibitory role of MAD2L2 in CRC development and suggested that MAD2L2 functioned as a tumor suppressor in CRC through the down‐regulation of NCOA3. This evidence concerns the gene NCOA3 and colorectal carcinoma.